Psychemedics Co. (NASDAQ:PMD) Short Interest Update

by · The Cerbat Gem

Psychemedics Co. (NASDAQ:PMD – Get Free Report) saw a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 13,900 shares, a drop of 43.3% from the October 15th total of 24,500 shares. Based on an average trading volume of 38,700 shares, the short-interest ratio is currently 0.4 days. Approximately 0.3% of the company’s stock are sold short.

Psychemedics Price Performance

Shares of Psychemedics stock remained flat at $2.34 during midday trading on Wednesday. The company had a trading volume of 35,819 shares, compared to its average volume of 17,638. The firm has a 50-day moving average price of $2.32 and a 200 day moving average price of $2.34. The firm has a market cap of $13.79 million, a PE ratio of -4.61 and a beta of 0.65. Psychemedics has a 52 week low of $1.63 and a 52 week high of $3.93.

Psychemedics (NASDAQ:PMD – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.14) EPS for the quarter. The firm had revenue of $4.73 million for the quarter. Psychemedics had a negative net margin of 14.59% and a negative return on equity of 47.50%.

About Psychemedics

(Get Free Report)

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol.

Featured Articles